Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 3, 1999, Pages 251-261

  Mück, Wolfgang ^a   Mai, Ingrid ^a   Fritsche, Lutz ^a   Ochmann, Klaus ^a   Rohde, Gabriele ^a   Unger, Sigrun ^a   Johne, Andreas ^a   Bauer, Steffen ^a   Budde, Klemens ^a   Roots, Ivar ^a   Neumayer, Hans Hellmut ^a   Kuhlmann, Jochen ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; AZATHIOPRINE; BENZBROMARONE; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CLONIDINE; CLONIDINE DERIVATIVE; CYCLOSPORIN; CYCLOSPORIN A; CYCLOSPORIN DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; POLYCLONAL ANTIBODY; PREDNISOLONE; VITAMIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CLEARANCE; KIDNEY TRANSPLANTATION; LIVER CLEARANCE; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

EID: 0033064071     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70104-9     Document Type: Article

References (41)

1. 1. Pirsch JD, D'Alessandro AM, Sollinger HW, Knechtle SJ, Reed A, Kalayoglu M, et al. Hyperlipidemia and transplantation: etiologic factors and therapy. J Am Soc Nephrol 1992;2:238-42.
2. 2. Kobashigawa JA, Murphy FL, Stevenson LW, Moriguchi JD, Kawata N, Kamjoo P, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990;82(suppl IV):281-3.
3. 3. Campana C, Iacona I, Regazzi MB, Gavazzi A, Perani G, Raddato V, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Ann Pharmacother 1995;29:235-9.
4. 4. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation [letter]. N Engl J Med 1988; 318:48.
5. 5. Corpier CL, Jones PH, Suki WN, Lederer ED, Quinones MA, Schmidt SW, Young JB. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988;260:239-41.
6. 6. Holdaas H, Hartmann A, Sternstrøm J, Dahl KJ, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995;76:102A-6A.
7. 7. Cheung AK, DeVault GA Jr, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993;3:1884-91.
8. 8. Regazzi MB, Iacona I, Campana C, Raddato V, Lesi C, Perani G, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993;25:2732-4.
9. 9. Olbricht C, Wanner C, Eisenhauer T, Kliem V, Doll R, Boddaert M, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin Pharmacol Ther 1997;62:311-21.
10. 10. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65:410-3.
11. 11. Mai I, Bauer S, Fritsche L, Ochmann K, Mück W, Rohde G, et al. Single-dose pharmacokinetics of a new HMG-CoA reductase inhibitor in renal transplant patients treated with cyclosporine A (CsA) [abstract]. Eur J Clin Pharmacol 1997;52(suppl):A137.
12. 12. Bischoff H, Angerbauer R, Bender J, Bischoff E, Faggiotto A, Petzinna D, et al. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. Atherosclerosis 1997;135:119-30.
13. 13. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 1997;35:255-60.
14. 14C]BAY w 6228: biotransformation in human liver microsomes in vitro - characterization of primary metabolite pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997;25:321-31.
15. 15. Radtke M, Boberg M, Kanhai W, Kern A, Leega A, Nowak K. Cerivastatin: identification of human CYP-450 isoforms involved in the biotransformation of the drug and two active metabolites [abstract]. Proceedings of the 8th North American ISSX Meeting, Hilton Head (SC); October 2-30, 1997. p. 109.
16. 16. Bischoff H, Angerbauer R, Boberg M, Schmidt D. Cerivastatin: high enzyme affinity and active metabolites contribute to its high pharmacological activity [abstract]. Atherosclerosis 1997;130(suppl):S25.
17. 17. Krol GJ, Beck GW, Ritter W, Lettieri JT. LC separation and induced fluorometric detection of rivastatin in blood plasma. J Pharm Biomed Anal 1993;11:1269-75.
18. 18. Laim YWF, Banerji S, Hatfiled C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997;32:30-57.
19. 19. Vormfelde SV, Freudenthaler S, Mück W, Schmage N, Kuhlmann J, Gundert-Remy, et al. Cerivastatin, an inhibitor of the HMG-CoA reductase, has no need for dose adjustment in renal dysfunction [abstract]. Eur J Clin Pharmacol 1997;52(suppl):A521.
20. 20. Campana C, Regazzi MB, Buggia I, Molinaro M. Clinically significant drug interactions with cyclosporin: un update. Clin Pharmacokinet 1996;30:141-79.
21. 21. Mück W. Thorough assessment of interaction profile supports safe therapeutic use of statins: focus on cerivastatin. Drugs 1998;56(suppl 1):15-23.
22. 22. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin; IV: identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
23. 23. Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ, et al. In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic 450s. Drug Metab Dispos 1997;25:1191-9.
24. 24. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664-5.
25. 25. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
26. 26. Bottorff MB, Behrens DH, Gross A, Markel MB. Differences in metabolism of lovastatin and pravastatin as assessed by CYP 3A inhibition by erythromycin [abstract]. Pharmacotherapy 1997;17:84.
27. 27. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
28. 28. Kitazawa E, Tamura N, Iwabuchi H, Uchiyama M, Muramatsu S, Takahagi H, et al. Biotransformation of pravastatin sodium; I: mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993;192: 597-602.
29. 29. Transon C, Leeman T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
30. 30. Kantola T, Kivistö KT, Neuvonen PJ. Differential effects of itraconazole on fluvastatin and lovastatin pharmacokinetics [abstract]. Eur J Clin Pharmacol 1997;52(suppl):A134.
31. 31. Steinke W, Yamashita S, Tabei M, Ahr HJ, Beckermann B, Domdey-Bette A, et al. Cerivastatin, a new inhibitor of HMG-CoA reductase: pharmacokinetics in rats and dogs. Jpn Pharmacol Ther 1996;24:S1217-37.
32. 32. Smith PF, Eydelloth S, Grossman SJ, Stubbs J, Schwartz MS, Germershausen JI, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991;257:1225-35.
33. 33. Yamazaki M, Suzuki H, Hanano M, Tokui T, Komai T, Sugiyama Y. Na+-Independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993;264:G36-44.
34. 34. Kadmon M, Klünemann C, Böhme M, Ishikawa T, Gorgas K, Otto G, et al. Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. Gastroenterology 1993;104:1507-14.
35. 35. Stapf V, Thalhammer T, Huber-Huber R, Felberbauer F, Gajdzik L, Graf J. Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver. Anticancer Res 1994;14:581-6.
36. 36. Ikeda T, Ishigami M, Komai T, Yamazoe Y. Inhibition of hepatic cytochrome P450 isoform, CYP3A, by 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors [abstract]. Atherosclerosis 1997;134:S135.
37. 37. Li PKT, Mak TWL, Wang AYM, Lee YT, Leung CB, Lui SF, et al. The interaction of fluvastatin and cyclosporine A in renal transplant patients. Int J Clin Pharmacol Ther 1995;33:246-8.
38. 38. Kuo PC, Kirshenbaum JM, Gordon J, Laffel G, Young P, DiSesa VJ, et al. Lovastatin therapy for hypercholesterolemia in cardiac transplant patients. Am J Cardiol 1989;64:631-5.
39. 39. Cassem JD, Hamilton MA, Albanese E, Sabad JA, Kobashigawa JA. Does pravastatin affect cyclosporine pharmacokinetics in cardiac transplant recipients [abstract]. J Invest Med 1997;45:139A.
40. 40. Reiss WG, Hanes D, White M, Hiehn SE, Klassen D, Bartlett S, et al. Examination of the potential interaction between HMG-CoA reductase inhibitors and cyclosporine in transplant patients [abstract]. Pharmacotherapy 1996;16:511.
41. 41. Akhlaghi F, McLachlan AJ, Keogh AM, Brown KF. Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. Br J Clin Pharmacol 1997;44:537-42.